Loss of Function in Phenylketonuria Is Caused by Impaired Molecular Motions and Conformational Instability

2008/06/06 by Søren W. Gersting, Kristina F. Kemter, Kristina Kemter +7 · 26 citations
Biochemistry, Genetics and Molecular Biology · Neuroscience · #Metabolism and Genetic Disorders #Mitochondrial Function and Pathology #Genetic Neurodegenerative Diseases

paper · pdf · doi:10.1016/j.ajhg.2008.05.013

Cited by

• Proteasomal control of transcription factors: mechanisms, regulation and dysregulation
• Up to date knowledge on different treatment strategies for phenylketonuria. [europepmc]
• Cystathionine beta-synthase mutants exhibit changes in protein unfolding: conformational analysis of misfolded variants in crude cell extracts. [europepmc]
• The role of protein structural analysis in the next generation sequencing era. [europepmc]
• A new model for allosteric regulation of phenylalanine hydroxylase: implications for disease and therapeutics. [europepmc]
• Characterization of two pathogenic mutations in cystathionine beta-synthase: different intracellular locations for wild-type and mutant proteins. [europepmc]
• Genotype-phenotype associations in French patients with phenylketonuria and importance of genotype for full assessment of tetrahydrobiopterin responsiveness. [europepmc]
• First structure of full-length mammalian phenylalanine hydroxylase reveals the architecture of an autoinhibited tetramer. [europepmc]
• New protein structures provide an updated understanding of phenylketonuria. [europepmc]
• Biophysical analysis of the effect of chemical modification by 4-oxononenal on the structure, stability, and function of binding immunoglobulin protein (BiP). [europepmc]
• Tetrahydrobiopterin treatment reduces brain L-Phe but only partially improves serotonin in hyperphenylalaninemic ENU1/2 mice. [europepmc]
• PAIRUP-MS: Pathway analysis and imputation to relate unknowns in profiles from mass spectrometry-based metabolite data. [europepmc]
• ProtCID: a data resource for structural information on protein interactions. [europepmc]
• Animal Model Contributions to Congenital Metabolic Disease. [europepmc]
• Protein Degradation and the Pathologic Basis of Phenylketonuria and Hereditary Tyrosinemia. [europepmc]
• Naturally-Occurring Rare Mutations Cause Mild to Catastrophic Effects in the Multifunctional and Cancer-Associated NQO1 Protein. [europepmc]
• E3 Ubiquitin Ligase APC/C Cdh1 Regulation of Phenylalanine Hydroxylase Stability and Function. [europepmc]
• Modulation of Human Phenylalanine Hydroxylase by 3-Hydroxyquinolin-2(1H)-One Derivatives. [europepmc]
• A retrospective study on disease management in children and adolescents with phenylketonuria during the Covid-19 pandemic lockdown in Austria. [europepmc]
• Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency. [europepmc]
• Engineering Organoids for in vitro Modeling of Phenylketonuria. [europepmc]
• Deubiquitinase USP19 extends the residual enzymatic activity of phenylalanine hydroxylase variants. [europepmc]
• Detection of Single-Nucleotide and Copy Number Defects Underlying Hyperphenylalaninemia by Next-Generation Sequencing. [europepmc]
• Use of pure recombinant human enzymes to assess the disease-causing potential of missense mutations in urea cycle disorders, applied to N-acetylglutamate synthase deficiency. [europepmc]
• Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1. [europepmc]
• Proteasomal control of transcription factors: mechanisms, regulation and dysregulation. [europepmc]